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Epidermal growth factor receptor (EGFR) mutation testing is now a standard part of the management of non– small-
cell lung cancer, and it is crucial to identify which mutations 
are associated with benefits from tyrosine kinase inhibitors 
(TKIs) and how to manage cases with unexpected genotyping 
results. Most adenocarcinoma-associated EGFR mutations 
are in-frame deletions in exon 19 or point mutations in exon 
21 (L858R). These mutations predict marked benefits from 
treatment with EGFR-TKIs. Among EGFR mutations, exon 
19 insertions have been rarely described in the literature and 
have uncertain clinical significance.
CASE REPORT
In January 2011, a 68-year-old man was referred to our 
hospital with a T2bN2M1b (stage IV) adenocarcinoma in the 
right lung. Computed tomography scans showed a 56.4-mm 
mass in the right lower lobe (Fig. 1A), and positron emission 
tomography scan showed multiple bone metastases. An 18 
base pair insertion in exon 19 (I744_K745insKIPVAI; Fig. 2) 
was detected on standard reverse transcription–polymerase 
chain reaction coupled with direct sequencing. The patient 
was initially started on palliative radiation therapy, with the 
left femur and cervical vertebrae receiving a total dose of 30 
Gy in 10 fractions for each metastasis. After palliative radia-
tion therapy, we selected treatment with gefitinib (daily dose, 
250 mg) although the clinical relevance of this mutation was 
not known. Response assessments by computed tomography 
scans revealed partial response according to the Response 
Evaluation Criteria in Solid Tumors, and the maximum 
tumor-reduction rate was 43.7% (Fig. 1B). Clinical response 
was maintained for 4.2 months. After disease progression, 
the patient selected the best supportive care and died after 10 
months of gefitinib treatment.
DISCUSSION
From 2000 to 2012, six cases in our hospital tested posi-
tive for EGFR exon 19 insertions. Of these six cases, three 
were evaluated for gefitinib sensitivity (Table 1). Two of three 
cases (66.6%) with lung cancer harboring EGFR exon 19 
insertions responded to gefitinib. However, time to progression 
in our cohort was relatively short (mean, 5.9 months). The clas-
sical responsive mutations are deletions in exon 19 and L858R 
in exon 21,1 and a recent article has described the clinical cor-
relations of rare mutations in exon 19 insertions.2 In that study, 
three of four patients with EGFR exon 19 insertions responded 
to TKI, suggesting a similar response to TKIs as exon 19 dele-
tion mutations. However, the number of cases remains small 
and it is unclear whether EGFR exon 19 insertions have the 
same progression-free and overall survival as the classic muta-
tions, and the same sensitivity in other ethnicities.
In our study, lung cancers harboring EGFR exon 19 
insertions exhibit clinical characteristics similar to lung can-
cers carrying common EGFR mutations, with a tendency to 
occur in never smokers. Looking at the insertion sequences, 
there is a consistent substitution seen, and this contrasts with 
insertions in exon 20 of EGFR.3 Our retrospective analysis of 
treatment effectiveness is limited in its ability because of the 
small number of lung cancers harboring exon 19 insertions.
In conclusion, we observed good clinical response, but 
a relatively short time to progression in the Japanese cases of 
exon 19 insertions, although further experiences are required 
to characterize this rare mutation.
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FIGURE 1.  Computed tomography scan of chest: (A) before 
treatment; (B) 2 months after treatment with gefitinib.
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TABLE 1.  Clinical Characteristics of Patients with Lung Cancers Harboring EGFR Exon 19 Insertions
Case Age/Sex Smoking Statusa Stage Length (bp) Amino Acid Sequence Pattern TTP (mo)/Response to Gefitinib
1 68/M 50 IV 18 p.I744_K745
ins KIPVAI
4.2/PR
2 51/F 0 IV 18 p.I744_K745
ins KIPVAI
4.9/SD
3 63/F 0 IIIAb 18 p.I744_K745
ins KIPVAI
8.8/PR
aPack-years.
bGefitinib was started for relapse after surgery.
TTP, time to progression; PR, partial response; SD, stable disease; bp, base pair.
I744_K745 ins KIPVAI 
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FIGURE 2.  Mutant form of epidermal growth factor recep-
tor insertion (I744_K745 ins KIPVAI) in exon 19 was identified 
by reverse transcription-polymerase chain reaction coupled 
with direct sequencing. Arrow shows nucleotide transition 
from C to T.
